WuXi AppTec taps Altasciences to support IND platform

By Maggie Lynch

- Last updated on GMT

(Image: Getty/MangoStar_Studio)
(Image: Getty/MangoStar_Studio)

Related tags Investigational new drug Wuxi apptec Clinical research CRO IND applications Altasciences

Altasciences will work with WuXi AppTec to support its investigational new drug platform designed to manage and accelerate IND applications.

The contract research organization (CRO), Altasciences, will provide its clinical pharmacology, first-in-human and proof-of-concept trials, program management and other full-service solutions to support early phase clinical services for WIND, WuXi AppTec’s investigational new drug (IND) platform.

The platform combines CRO services with program management and regulatory support for IND applications.

Per the agreement, Altasciences will provide full-service early phase clinical solutions to the partnership to support the addition of the IND platform. Altasciences has agreed to provide clinical pharmacology, first-in-human and proof-of-concept trials, program management, and data management, among other services to streamline early phase clinical processes for WuXi’s IND programs.

A spokesperson for WuXi Apptec told us, “The objective of WIND is to support the full scope of drug development programs, from IND-enabling studies to document preparation and submission. By partnering with Altasciences, WuXi can be more flexible with scheduling multiple components of the drug development process from lead candidate selection through to proof of concept, therefore, accelerating the IND process.”

WuXi Clinical, the clinical CRO arm of WuXi AppTec will manage the partnership between the two companies. The WuXi AppTec spokesperson told us the clinical arm had been looking to partner in North America in an aim to complement its current Phase I offering and support the IND platform.

Additionally, a number of senior executives at Altasciences have previously worked at WuXi, which the company believes will build a true collaboration, according to the WuXi spokesperson.

Related news

Show more

Related products

show more

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Validate clinical study data with Formedix CORE

Validate clinical study data with Formedix CORE

Content provided by Formedix | 19-Jun-2023 | White Paper

In April 2023 at the CDISC Europe Interchange, we launched Formedix CORE, the first free-to-use, downloadable application encompassing the CDISC Open Rules...

Related suppliers

Follow us

Products

View more

Webinars